All News
Treatment Sequences Define Subphenotypes in RA Patients
An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time.
Read Article
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?
Read Article
Cancer Risk From RA, Not the Drugs
While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy.
Read Article
Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn
Links:
Dr. John Cush RheumNow ( View Tweet)
Medicare and Commercial claims analysis shows
1 #RA pts at risk for H Zoster
2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ
3 Higher total costsalso higher in month after HZ
https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy
Links:
Dr. John Cush RheumNow ( View Tweet)
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L
Links:
Dr. John Cush RheumNow ( View Tweet)
Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1
Links:
Dr. John Cush RheumNow ( View Tweet)
HRT for RA? Not Yet
Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy.
@AurelieRheumo
https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/0dV23VPDQH https://t.co/HfKhji40vU
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Should you Assess Rheumatoid Factor Serially?
Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy.
https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: De Novo Renal Nephritis Flares During Belimumab Trials
Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy.
https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu
Links:
Dr. John Cush RheumNow ( View Tweet)
How Often Do You Monitor MTX?
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
https://t.co/niPFjQTenh https://t.co/JyL8t6EexT
Links:
Dr. John Cush RheumNow ( View Tweet)
Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9
Links:
Dr. John Cush RheumNow ( View Tweet)
Chronic Pain Management tools
1 Medication
2 Physical Therapy
3 Cognitive-Behavioral Therapy
4 Mindfulness Meditation
5 Acupuncture
6 Massage
7 Heat/Cold
8 TENS
9 Yoga/Tai Chi
10 Support groups https://t.co/VBvYR8VK16 https://t.co/tbfPnL1VEH
Links:
Dr. John Cush RheumNow ( View Tweet)
Using Optum claims data from 2009 to 2021, they identified 524 IgG4-RD pts (mean age 56 yrs), incidence increased over time 0.78 to 1.39/100K Pt Yrs 2015 and 2019. Prevalence (1/19) was 5.3/100K Pt-Yrs, w/ mortality rate 3.42/100 Pt-Yrs (HR 2.51) https://t.co/22eIjtC7kp https://t.co/8RlEtZiX9j
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd
Links:
Dr. John Cush RheumNow ( View Tweet)